(IDNA) iShares Genomics - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46435U1925 • Health
IDNA: Genomics, Immunology, Healthcare, Biotechnology, Pharmaceuticals, Medical
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.
Additional Sources for IDNA ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IDNA ETF Overview
| Market Cap in USD | 125m |
| Category | Health |
| TER | 0.47% |
| IPO / Inception | 2019-06-11 |
IDNA ETF Ratings
| Growth 5y | -30.4% |
| Fundamental | - |
| Dividend | 48.3% |
| Rel. Strength Industry | -97.9 |
| Analysts | - |
| Fair Price Momentum | 19.94 USD |
| Fair Price DCF | - |
IDNA Dividends
| Dividend Yield 12m | 0.99% |
| Yield on Cost 5y | 0.81% |
| Annual Growth 5y | 13.09% |
| Payout Consistency | 82.8% |
IDNA Growth Ratios
| Growth Correlation 3m | -74.7% |
| Growth Correlation 12m | 24.8% |
| Growth Correlation 5y | -75.2% |
| CAGR 5y | -4.01% |
| CAGR/Mean DD 5y | -0.11 |
| Sharpe Ratio 12m | -0.10 |
| Alpha | -25.45 |
| Beta | 0.95 |
| Volatility | 27.02% |
| Current Volume | 16.2k |
| Average Volume 20d | 34.4k |
What is the price of IDNA stocks?
As of January 23, 2025, the stock is trading at USD 22.46 with a total of 16,247 shares traded.
Over the past week, the price has changed by +2.46%, over one month by -1.45%, over three months by -6.86% and over the past year by +0.56%.
As of January 23, 2025, the stock is trading at USD 22.46 with a total of 16,247 shares traded.
Over the past week, the price has changed by +2.46%, over one month by -1.45%, over three months by -6.86% and over the past year by +0.56%.
Is iShares Genomics a good stock to buy?
Probably not. Based on ValueRay Analyses, iShares Genomics (NYSE ARCA:IDNA) is currently (January 2025) not a good stock to buy. It has a ValueRay Growth Rating of -30.40 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IDNA as of January 2025 is 19.94. This means that IDNA is currently overvalued and has a potential downside of -11.22%.
Probably not. Based on ValueRay Analyses, iShares Genomics (NYSE ARCA:IDNA) is currently (January 2025) not a good stock to buy. It has a ValueRay Growth Rating of -30.40 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IDNA as of January 2025 is 19.94. This means that IDNA is currently overvalued and has a potential downside of -11.22%.
Is IDNA a buy, sell or hold?
iShares Genomics has no consensus analysts rating.
iShares Genomics has no consensus analysts rating.
What are the forecast for IDNA stock price target?
According to ValueRays Forecast Model, IDNA iShares Genomics will be worth about 22.1 in January 2026. The stock is currently trading at 22.46. This means that the stock has a potential downside of -1.47%.
According to ValueRays Forecast Model, IDNA iShares Genomics will be worth about 22.1 in January 2026. The stock is currently trading at 22.46. This means that the stock has a potential downside of -1.47%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 22.1 | -1.5% |